Transient overexposure of neuregulin 3 during early postnatal development impacts selective behaviors in adulthood

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Paterson, Clare ^a   Law, Amanda J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; NEU DIFFERENTIATION FACTOR; NEUREGULIN 3; PROTEIN KINASE B; UNCLASSIFIED DRUG; NRG3 PROTEIN, HUMAN; PEPTIDE;

ADULT; ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; AUTISM; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; CONTROLLED STUDY; EXPERIMENTAL HYPERACTIVITY; MALE; MEMORY; MOUSE; NEWBORN; NONHUMAN; PERINATAL DEVELOPMENT; POSTNATAL DEVELOPMENT; PREPULSE INHIBITION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SCHIZOPHRENIA; SENSORY GATING; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; STARTLE REFLEX; ANIMAL; ANIMAL BEHAVIOR; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; METABOLISM; MOTOR ACTIVITY; PHENOTYPE; PSYCHOMOTOR PERFORMANCE; SYNTHESIS;

ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; HUMANS; MALE; MEMORY; MICE; MOTOR ACTIVITY; NEUREGULINS; PEPTIDES; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-AKT; PSYCHOMOTOR PERFORMANCE; RECEPTOR, ERBB-4; REFLEX, STARTLE; SIGNAL TRANSDUCTION;

EID: 84905662220     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104172     Document Type: Article

References (54)

1. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, et al. (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320: 539-543. (Pubitemid 351590668)
2. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, et al. (2008) Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 82: 477-488.
3. Elia J, Gai X, Xie HM, Perin JC, Geiger E, et al. (2010) Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol Psychiatry 15: 637-646.
4. Guilmatre A, Dubourg C, Mosca AL, Legallic S, Goldenberg A, et al. (2009) Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch Gen Psychiatry 66: 947-956.
5. Mefford HC, Cooper GM, Zerr T, Smith JD, Baker C, et al. (2009) A method for rapid, targeted CNV genotyping identifies rare variants associated with neurocognitive disease. Genome Res 19: 1579-1585.
6. Hatzimanolis A, McGrath JA, Wang R, Li T, Wong PC, et al. (2013) Multiple variants aggregate in the neuregulin signaling pathway in a subset of schizophrenia patients. Transl Psychiatry 3: e264.
7. Fallin MD, Lasseter VK, Wolyniec PS, McGrath JA, Nestadt G, et al. (2003) Genomewide linkage scan for schizophrenia susceptibility loci among Ashkenazi Jewish families shows evidence of linkage on chromosome 10q22. Am J Hum Genet 73: 601-611. (Pubitemid 37076272)
8. Faraone SV, Hwu HG, Liu CM, Chen WJ, Tsuang MM, et al. (2006) Genome scan of Han Chinese schizophrenia families from Taiwan: confirmation of linkage to 10q22.3. Am J Psychiatry 163: 1760-1766. (Pubitemid 44522485)
9. Balciuniene J, Feng N, Iyadurai K, Hirsch B, Charnas L, et al. (2007) Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with cognitive and behavioral abnormalities. Am J Hum Genet 80: 938-947. (Pubitemid 46668462)
10. Wang YC, Chen JY, Chen ML, Chen CH, Lai IC, et al. (2008) Neuregulin 3 genetic variations and susceptibility to schizophrenia in a Chinese population. Biol Psychiatry 64: 1093-1096.
11. Chen PL, Avramopoulos D, Lasseter VK, McGrath JA, Fallin MD, et al. (2009) Fine mapping on chromosome 10q22-q23 implicates Neuregulin 3 in schizophrenia. Am J Hum Genet 84: 21-34.
12. Morar B, Dragovic M, Waters FA, Chandler D, Kalaydjieva L, et al. (2011) Neuregulin 3 (NRG3) as a susceptibility gene in a schizophrenia subtype with florid delusions and relatively spared cognition. Mol Psychiatry 16: 860-866.
13. Kao WT, Wang Y, Kleinman JE, Lipska BK, Hyde TM, et al. (2010) Common genetic variation in Neuregulin 3 (NRG3) influences risk for schizophrenia and impacts NRG3 expression in human brain. Proc Natl Acad Sci U S A 107: 15619-15624.
14. Meier S, Strohmaier J, Breuer R, Mattheisen M, Degenhardt F, et al. (2013) Neuregulin 3 is associated with attention deficits in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol 16: 549-556.
15. Tost H, Callicott JH, Rasetti R, Vakkalanka R, Mattay VS, et al. (2014) Effects of neuregulin 3 genotype on human prefrontal cortex physiology. J Neurosci 34: 1051-1056.
16. Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, et al. (1997) Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci U S A 94: 9562-9567. (Pubitemid 27408101)
17. Deakin IH, Law AJ, Oliver PL, Schwab MH, Nave KA, et al. (2009) Behavioural characterization of neuregulin 1 type I overexpressing transgenic mice. Neuroreport 20: 1523-1528.
18. Yin DM, Chen YJ, Lu YS, Bean JC, Sathyamurthy A, et al. (2013) Reversal of behavioral deficits and synaptic dysfunction in mice overexpressing neuregulin 1. Neuron 78: 644-657.
19. Del Pino I, Garcia-Frigola C, Dehorter N, Brotons-Mas JR, Alvarez-Salvado E, et al. (2013) Erbb4 deletion from fast-spiking interneurons causes schizophrenia-like phenotypes. Neuron 79: 1152-1168.
20. Longart M, Liu Y, Karavanova I, Buonanno A (2004) Neuregulin-2 is developmentally regulated and targeted to dendrites of central neurons. J Comp Neurol 472: 156-172. (Pubitemid 38429017)
21. Assimacopoulos S, Grove EA, Ragsdale CW (2003) Identification of a Pax6-dependent epidermal growth factor family signaling source at the lateral edge of the embryonic cerebral cortex. J Neurosci 23: 6399-6403. (Pubitemid 36909864)
22. Carteron C, Ferrer-Montiel A, Cabedo H (2006) Characterization of a neural-specific splicing form of the human neuregulin 3 gene involved in oligodendrocyte survival. J Cell Sci 119: 898-909.
23. Kato T, Abe Y, Sotoyama H, Kakita A, Kominami R, et al. (2011) Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol Psychiatry 16: 307-320.
24. Abe Y, Namba H, Kato T, Iwakura Y, Nawa H (2011) Neuregulin-1 signals from the periphery regulate AMPA receptor sensitivity and expression in GABAergic interneurons in developing neocortex. J Neurosci 31: 5699-5709.
25. Abe Y, Odaka M, Inagaki F, Lax I, Schlessinger J, et al. (1998) Disulfide bond structure of human epidermal growth factor receptor. J Biol Chem 273: 11150-11157. (Pubitemid 28204963)
26. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, et al. (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787. (Pubitemid 35291060)
27. Law AJ, Wang Y, Sei Y, O'Donnell P, Piantadosi P, et al. (2012) Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110delta inhibition as a potential therapeutic strategy. Proc Natl Acad Sci U S A 109: 12165-12170.
28. Papaleo F, Crawley JN, Song J, Lipska BK, Pickel J, et al. (2008) Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci 28: 8709-8723.
29. Barker GR, Bird F, Alexander V, Warburton EC (2007) Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex. J Neurosci 27: 2948-2957. (Pubitemid 46438982)
30. Barker GR, Warburton EC (2011) When is the hippocampus involved in recognition memory? J Neurosci 31: 10721-10731.
31. Moy SS, Nadler JJ, Perez A, Barbaro RP, Johns JM, et al. (2004) Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav 3: 287-302. (Pubitemid 39277416)
32. Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P, European NanoBioPharmaceutics Research I (2009) Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol 87: 212-251.
33. Futamura T, Kakita A, Tohmi M, Sotoyama H, Takahashi H, et al. (2003) Neonatal perturbation of neurotrophic signaling results in abnormal sensori-motor gating and social interaction in adults: implication for epidermal growth factor in cognitive development. Mol Psychiatry 8: 19-29. (Pubitemid 36188570)
34. Carlsson T, Schindler FR, Hollerhage M, Depboylu C, Arias-Carrion O, et al. (2011) Systemic administration of neuregulin-1beta1 protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem 117: 1066-1074.
35. Kastin AJ, Akerstrom V, Pan W (2004) Neuregulin-1-beta1 enters brain and spinal cord by receptor-mediated transport. J Neurochem 88: 965-970. (Pubitemid 38199318)
36. Hobbs SS, Coffing SL, Le AT, Cameron EM, Williams EE, et al. (2002) Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene 21: 8442-8452. (Pubitemid 36054885)
37. Henck JW, Reindel JF, Anderson JA (2001) Growth and development in rats given recombinant human epidermal growth factor(1-48) as neonates. Toxicol Sci 62: 80-91. (Pubitemid 32611364)
38. Falls DL (2003) Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284: 14-30.
39. Deakin IH, Nissen W, Law AJ, Lane T, Kanso R, et al. (2012) Transgenic overexpression of the type I isoform of neuregulin 1 affects working memory and hippocampal oscillations but not long-term potentiation. Cereb Cortex 22: 1520-1529.
40. Duffy L, Cappas E, Lai D, Boucher AA, Karl T (2010) Cognition in transmembrane domain neuregulin 1 mutant mice. Neuroscience 170: 800-807.
41. Chen YJ, Johnson MA, Lieberman MD, Goodchild RE, Schobel S, et al. (2008) Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci 28: 6872-6883.
42. Mizuno M, Sotoyama H, Namba H, Shibuya M, Eda T, et al. (2013) ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions. Transl Psychiatry 3: e252.
43. Shamir A, Kwon OB, Karavanova I, Vullhorst D, Leiva-Salcedo E, et al. (2012) The importance of the NRG-1/ErbB4 pathway for synaptic plasticity and behaviors associated with psychiatric disorders. J Neurosci 32: 2988-2997.
44. Turner JR, Ray R, Lee B, Everett L, Xiang J, et al. (2013) Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence. Mol Psychiatry.
45. Mahar I, Tan S, Davoli MA, Dominguez-Lopez S, Qiang C, et al. (2011) Subchronic peripheral neuregulin-1 increases ventral hippocampal neurogenesis and induces antidepressant-like effects. PLoS One 6: e26610.
46. Vullhorst D, Neddens J, Karavanova I, Tricoire L, Petralia RS, et al. (2009) Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus. J Neurosci 29: 12255-12264.
47. Bortolato M, Godar SC, Tambaro S, Li FG, Devoto P, et al. (2013) Early postnatal inhibition of serotonin synthesis results in long-term reductions of perseverative behaviors, but not aggression, in MAO A-deficient mice. Neuropharmacology 75: 223-232.
48. Dean B, Karl T, Pavey G, Boer S, Duffy L, et al. (2008) Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. Schizophr Res 99: 341-349. (Pubitemid 351249119)
49. Loos M, Mueller T, Gouwenberg Y, Wijnands R, van der Loo RJ, et al. (2014) Neuregulin-3 in the Mouse Medial Prefrontal Cortex Regulates Impulsive Action. Biol Psychiatry.
50. Sanchez MM, Ladd CO, Plotsky PM (2001) Early adverse experience as a developmental risk factor for later psychopathology: evidence from rodent and primate models. Dev Psychopathol 13: 419-449. (Pubitemid 33406337)
51. Portera-Cailliau C, Weimer RM, De Paola V, Caroni P, Svoboda K (2005) Diverse modes of axon elaboration in the developing neocortex. PLoS Biol 3: e272.
52. Grant E, Hoerder-Suabedissen A, Molnar Z (2012) Development of the corticothalamic projections. Front Neurosci 6: 53.
53. Lipska BK, Jaskiw GE, Weinberger DR (1993) Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 9: 67-75. (Pubitemid 23242602)
54. Saunders RC, Kolachana BS, Bachevalier J, Weinberger DR (1998) Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine. Nature 393: 169-171. (Pubitemid 28242256)